Document Detail


Superiority of oral verapamil therapy to digoxin in treatment of chronic atrial fibrillation.
MedLine Citation:
PMID:  6337787     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
The efficacy and safety of oral verapamil, 240 mg, with or without digoxin were studied in 52 patients with chronic atrial fibrillation at rest, and during mild and maximal exercise. Twenty-four patients were studied during the following therapeutic modalities: no therapy; digoxin, 0.25 mg and 0.5 mg daily; digoxin, 0.25 mg and verapamil; and verapamil alone. Heart rate at rest and during all levels of exercise was decreased significantly (p less than 0.005), either by combining digoxin with verapamil or by verapamil therapy alone. In contrast, the excessive heart rate response to exercise was not prevented by digoxin even with good serum concentrations. The improved control of heart rate with verapamil was associated with a significantly improved exercise capacity. Verapamil is an important and safe modality of treatment, with or without digoxin, in the long-term control of heart rate in chronic atrial fibrillation. It is superior to digoxin in controlling the ventricular rate and in improving exercise capacity.
Authors:
R Lang; H O Klein; E Weiss; D David; P Sareli; A Levy; J Guerrero; E Di Segni; E Kaplinsky
Related Documents :
17335297 - Antianginal efficacy and safety of ivabradine compared with amlodipine in patients with...
7744087 - 24 h anti-anginal and anti-ischaemic effects with once daily felodipine. a double-blind...
2126727 - Clinical benefit of transdermal glyceryl trinitrate when used with an eight hour patch-...
9264427 - Effect of supplemental oral l-arginine on exercise capacity in patients with stable ang...
11006427 - Attention to metabolic hunger and its effects on helicobacter pylori infection.
7471617 - Bronchodilation and inhibition of induced asthma by adrenergic agonists.
Publication Detail:
Type:  Clinical Trial; Comparative Study; Controlled Clinical Trial; Journal Article    
Journal Detail:
Title:  Chest     Volume:  83     ISSN:  0012-3692     ISO Abbreviation:  Chest     Publication Date:  1983 Mar 
Date Detail:
Created Date:  1983-04-07     Completed Date:  1983-04-07     Revised Date:  2007-11-15    
Medline Journal Info:
Nlm Unique ID:  0231335     Medline TA:  Chest     Country:  UNITED STATES    
Other Details:
Languages:  eng     Pagination:  491-9     Citation Subset:  AIM; IM    
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Administration, Oral
Adult
Aged
Atrial Fibrillation / drug therapy*,  physiopathology
Clinical Trials as Topic
Digoxin / administration & dosage,  metabolism,  therapeutic use*
Drug Therapy, Combination
Exercise Test
Female
Half-Life
Heart Rate / drug effects
Humans
Male
Middle Aged
Time Factors
Verapamil / administration & dosage,  metabolism,  therapeutic use*
Chemical
Reg. No./Substance:
20830-75-5/Digoxin; 52-53-9/Verapamil

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Effects of labetalol in hypertensive patients with chronic obstructive pulmonary disease.
Next Document:  Role of prostaglandin and thromboxane biosynthesis in gastric necrosis produced by taurocholate and ...